市場調査レポート

エリスロポエチン(EPO)市場

Erythropoietin (EPO) Market Report: 2012 Edition

発行 Koncept Analytics 商品コード 252468
出版日 ページ情報 英文 48 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
エリスロポエチン(EPO)市場 Erythropoietin (EPO) Market Report: 2012 Edition
出版日: 2012年09月27日 ページ情報: 英文 48 Pages
概要

当レポートでは、日本および中国におけるESA/EPO製品市場について包括的分析を提供しており、国別の市場分析、市場の促進因子と課題、および競合情勢などについてまとめ、主要企業のプロファイルを含め、概略以下の構成でお届けいたします。

第1章 エリスロポエチン(EPO)

  • 概要
  • 遺伝子組換え型ヒトエリスロポエチン(rHuEPO)
  • 貧血およびその他の内科疾患をターゲットにしたEPOの使用

第2章 ESA/EPO製品の市場規模

  • 日本のエリスロポエチン市場
    • 日本で上市・開発中のEPO製品
    • 日本のESA/EPO製品市場
      • 市場額
      • 市場規模:製品別
      • 市場シェア:企業/製品別
    • 日本のESA/EPO製品市場展望
      • 全体的な市場予測
      • 製品収益の予測
  • 中国のエリスロポエチン市場
    • 中国のEPOおよびEPIAO市場規模
      • EPO市場の成長
      • EPO市場の規模:セグメント別
      • EPIAO市場の規模:セグメント別
    • 中国のEPIAO市場展望
      • セグメント別の展望
      • ESRD
      • 透析前

第3章 市場力学

  • 主要動向
    • 治験の戦略的展望
    • ポリシアル化に向かう傾向
    • 臨床差別化への注目
  • 産業の発展
    • 改良生体分子の開発
    • インドで実施中のErepoXenフェーズIIb静脈試験
    • バイオシミラーの出現
  • 成長促進因子
    • 慢性腎疾患(CKD)の増加事例
    • 世界の透析患者人口
    • 癌有病率の増加
    • オリジナル生物製剤の特許失効が迫る
    • 世界的な高齢者人口の増加
    • 医療費の上昇
  • 課題
    • 血栓症およびPRCAのリスク
    • 承認獲得に向けたさらなる治験の要求
    • EPOの不正使用
    • EPOの副作用
    • 価格圧力の増大

第4章 エリスロポエチン市場:競合情勢

  • 競合概要
  • 市場シェア

第5章 企業プロファイル

  • Amgen Inc.
    • 事業概要
    • 財務概要
    • 事業戦略
    • 戦略的アライアンスを通した成長
    • 買収への資本投下
  • Johnson & Johnson
    • 事業概要
    • 財務概要
    • 事業戦略
    • 財務リスクの最小化
    • 長期的成長への集中
  • Roche
    • 事業概要
    • 財務概要
    • 事業戦略
    • 革新への集中
    • 分子生物学で優れて突出
  • Hospira Inc.
    • 事業概要
    • 財務概要
    • 事業戦略
    • 新製品開発戦略
    • 新薬デリバリーフォーマット

図表

目次

Abstract

Description

With the advent of novel technology, companies operating in the healthcare/science/pharmaceutical/therapeutic area are now scaling new heights. Also this industry is boosted by the rising number of incidences of health related issues emanating from the changing lifestyle and rapidly evolving surrounding environment.

Amongst the respective industries of biological sciences, an upcoming industry is of EPO (Erythropoietin) and ESA (Erythropoietin Stimulating Agents). EPO is a glycoprotein hormone which regulates erythropoiesis i.e. the production of Red Blood Cells (RBC). EPO is mainly produced within the human kidneys by the interstitial fibroblasts in a close association with and tubular epithelial cells. But the production of endogenous EPO is marred in case of people suffering with renal anemia as the kidney remains inflamed and also in the instance of anemia occurring due to chemotherapy amongst cancer patients. EPO is also used for placating conditions like neurological disorders, post cardiac surgery term and other critical illness situations.

The ESA market takes into account the EPO products and other EPO stimulating agents. The synthetic ESAs available in the market are known as rHuEPO (Recombinant Human Erythropoietin) manufactured using DNA. It is similar to the natural human EPO. In the pharmaceutical drug market, 5 variants of ESAs are most prevalent viz. epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa.

This report provides a comprehensive analysis of the ESA/EPO product market of Japan and China. The competitive environment of the industry is quite fierce and challenging. On the global level, the top notch players in the EPO market include Amgen, Roche and Johnson & Johnson with Hospira being another potential constituent.

Herein, the market dynamics viz. the key trends (strategic outlook for clinical trials, inclination towards polysialylation and focus on clinical differentiation), industry developments (development of improved biological molecules, ErepoXen Phase IIb intravenous trial underway in India and advent of biosimilars), growth drivers (increasing cases chronic kidney disease (CKD), global dialysis patient population, increasing prevalence of cancer, upcoming patent expiries of original bio drugs, rising adult population worldwide and rising healthcare expenditure) and challenges (risk of thrombosis and PRCA, requirement of extensive clinical trials for obtaining approval, abusive uses of EPO, adverse effects of EPO and escalating price pressure) are also explicated.

Table of Contents

1. Erythropoietin (EPO)

  • 1.1 Overview
  • 1.2 Recombinant Human Erythropoietin (rHuEPO)
  • 1.3 Use of EPO in Treating Anemia and other Medical Conditions

2. ESA/EPO Product Market Size

  • 2.1 Japanese Erythropoietin Market
    • 2.1.1 EPO Products in Market/Under Development in Japan
    • 2.1.2 Japan's ESA/EPO Products Market
      • Market Value
      • Market Size by Products
      • Market Share by Companies/Products
    • 2.1.3 Japan's ESA/EPO Product Market Outlook
      • Overall Market Forecast
      • Product Revenue Forecast
  • 2.2 Chinese Erythropoietin Market
    • 2.2.1 China's EPO and EPIAO Market Size
      • EPO Market Growth
      • EPO Market Size by Segments
      • EPIAO Market Size by Segments
    • 2.2.2 China's EPIAO Market Outlook
      • Segment Outlook
      • ESRD
      • Pre-Dialysis
      • Oncology

3. Market Dynamics

  • 3.1 Key Trends
    • 3.1.1 Strategic Outlook for Clinical Trials
    • 3.1.2 Inclination towards Polysialylation
    • 3.1.3 Focus on Clinical Differentiation
  • 3.2 Industry Developments
    • 3.2.1 Development of improved Biological Molecules
    • 3.2.2 ErepoXen Phase IIb Intravenous Trial Underway in India
    • 3.2.3 Advent of Biosimilars
  • 3.3 Growth Drivers
    • 3.3.1 Increasing Cases Chronic Kidney Disease (CKD)
    • 3.3.2 Global Dialysis Patient Population
    • 3.3.3 Increasing Prevalence of Cancer
    • 3.3.4 Upcoming Patent Expiries of Original Bio Drugs
    • 3.3.5 Rising Adult Population Worldwide
    • 3.3.6 Rising Healthcare Expenditure
  • 3.4 Challenges
    • 3.4.1 Risk of Thrombosis and PRCA
    • 3.4.2 Requirement of Extensive Clinical Trials for Obtaining Approval
    • 3.4.3 Abusive Uses of EPO
    • 3.4.4 Adverse Effects of EPO
    • 3.4.5 Escalating Price Pressure

4. Erythropoietin Market - Competitive Landscape

  • Competitive Overview
  • Market Share

5. Company Profiles

  • 5.1 Amgen Inc.
    • Business Overview
    • Financial Overview
    • Business Strategies
    • Growth through Strategic Alliances
    • Capitalizing on Acquisitions
  • 5.2 Johnson & Johnson
    • Business Overview
    • Financial Overview
    • Business Strategies
    • Financial Risk Minimization
    • Concentration on Long Term Growth
  • 5.3 Roche
    • Business Overview
    • Financial Overview
    • Business Strategies
    • Focus on Innovation
    • Excellence in Molecular Biology
  • 5.4 Hospira Inc.
    • Business Overview
    • Financial Overview
    • Business Strategies
    • New Product Development Strategy
    • Novel Drug Delivery Formants

List of Charts

  • Stages of Erythropoiesis
  • Erythropoietin Response to Hypoxia
  • Japan's ESA Market Size (2004-2010)
  • Japan's ESA Market Size by Product (2010-2011)
  • Japan's ESA Market Share by Product (2010-2015E)
  • Japan's ESA Market Share by Company (2010-2015E)
  • Japan's ESA Market Size (2012E-2015E)
  • Japan's ESA Market Size by Product (2012E-2015E)
  • China's EPO Market Growth (2005 and 2010)
  • China's EPO Market Size by Usage Area (2007-2011)
  • China's EPIAO Market Size by Usage Area (2007-2011)
  • Worldwide Patients with End Stage Renal Disease (2005-2010)
  • Causes of ESRD in the US (2011)
  • Dialysis Patient Population Worldwide (2005-2015E)
  • Number of Cancer Cases Worldwide (2007-2011)
  • Rising Global Adult Population Above 20 years (2007-2012E)
  • Global Healthcare Spending (2005-2015E)
  • EPO Market Share (including biobetter) by Company (2010)
  • Amgen's Revenue Share by Business segment (2011)
  • Amgen's Revenues and Net Income (2011)
  • Johnson & Johnson's Revenue Share by Business Segments (2011)
  • Johnson & Johnson's Revenues and Net Earnings (2008-2011)
  • Roche's Revenue Share by Business Segments (2011)
  • Roche's Revenues and Net Income (2007-2011)
  • Hospira's Revenue Share by Business Segments (2011)
  • Hospira's Revenues & Net Income (2007-2011)

List of Tables

  • Drugs for anemia associated with chronic renal failure in Japan
  • Mircera Assumptions (2010-2015E)
  • Nesp Assumption (2010-2015E)
  • Espo Assumption (2010-2015E)
  • Epogin Assumption (2010-2015E)
  • Epoetin-alpha BS Assumptions (2010-2015E)
  • Japanese ESA Market Share by Product and by Company (2010-2015E)
  • Japan's ESA Product Revenues (2012E-2015E)
  • China's EPIAO Market Model for ESRD (2007-2011)
  • China's EPIAO Market Model for Pre-Dialysis (2007-2011)
  • China's EPO Market Model for Oncology (2007-2011)
  • China's EPIAO Opportunity Model for ESRD (2012E-2014E)
  • China's EPIAO Opportunity Model for Pre-Dialysis (2012E-2014E)
  • China's EPO Opportunity Model for Oncology (2012E-2014E)
  • Development of Novel Forms of Erythropoietin
  • Recombinant and Improved Formulations of Erythropoietin
  • Biosimilar Epoetins Currently Approved by the European Medicines Agency
  • Biosimilar Share (by Value) of the Short-acting Erythropoiesis-stimulating Agent
  • Market in the EU G5 Countries (2011)
  • Risk Factors for CKD
  • Expiry of Bio Drugs Patents in the Global Market (2013-2015)
Back to Top